Another question. (Yeah, I know...)
In an earlier thread you discussed the protection offered by the current vaccines (basically enhancing the immune response to virions advancing beyond the nasal / respiratory passages), vs. the development of “nasal vaccines”, which enhance a different antibody and which, if I understand it correctly, should hold down viral colonization in nasal / respiratory passages, and thereby reduce viral shedding greatly. I take it this 2nd class of vaccines is still several months “out”.
I guess my question is why were not the 2nd class of vaccines pursued first?
“ I guess my question is why were not the 2nd class of vaccines (nasal) pursued first?”
I don’t know. The FluMist nasal vaccine is limited to younger folks, so that potential market limitations may have scared developers - but also, the priority targets for vaccination are the elderly.